Skip to main content

Following in the footsteps of radiology, its brother in imaging analysis arms, digital pathology has recently become a popular canvas for artificial intelligence applications.

Startups like Ibex, previous Fierce 15 honoree Paige and current Fierce 15 winner PathAI have racked up a handful of regulatory approvals and hundreds of millions in funding for their respective AI-powered biopsy-reading technologies—and now, Verily is looking for a piece of the digital pathology pie.

The Alphabet subsidiary is already working with its sister company Google Health to develop AI algorithms that take over the burden of analyzing tissue samples from human pathologists, with an initial focus on assessing prostate cancer tumors.

A new partnership will bring those algorithms to the digital pathology platform developed by Utah-based Lumea, with an aim of improving objectivity and efficiency in diagnosing, prognosing and treating prostate cancer.

READ FULL ARTICLE 

Learn how comprehensive digital pathology that starts with the patient can help improve the quality of your practice, reduce costs, and scale your business here.

Leave a Reply